Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of AC-262536 and LGD-3303 — mechanism, side effects, legal status, and pricing.
AC-262536 is a non-peptide nonsteroidal selective androgen receptor modulator (SARM) with an azabicyclooctane naphthalene-carbonitrile structure. It acts as a partial AR agonist, showing tissue-selective anabolic effects in preclinical models. No human trials have been conducted, and it is not FDA-approved. SARMs are prohibited in athletic competition under WADA category S1.2.
LGD-3303 is a non-peptide small molecule belonging to the pyrrolo[3,2-f]quinolinone class of selective androgen receptor modulators (SARMs). It has never been approved by the FDA or any regulatory agency for human use, and no human clinical trials have been conducted or registered. LGD-3303 is prohibited under WADA's S1.2 category (Other Anabolic Agents), which covers all SARMs as a class. All available data are preclinical, derived from in vitro AR binding assays and in vivo studies in castrated rats and horses.
AC-262536
LGD-3303
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
AC-262536
LGD-3303
COA corpus from Disclosed Labs — independently tested batches only.
AC-262536
No COA data yet.
Submit testing data →LGD-3303
2
COAs
99.0%
Avg purity
2
Labs
No human data exist. All pharmacology derives from a single 2008 preclinical publication. In castrated male rats dosed chronically for two weeks, AC-262536 significantly increased levator ani muscle growth and suppressed elevated luteinizing hormone, while producing only weak effects on prostate and seminal vesicle weight compared to testosterone. The compound has also been included in validated analytical panels for SARM residue surveillance in bovine muscle tissue, reflecting its presence in food-safety monitoring rather than therapeutic development.
No human data exist for LGD-3303. No completed or registered clinical trials were found on ClinicalTrials.gov, and no PubMed record of a Phase 1 or later human trial exists. In castrated Sprague-Dawley rats, LGD-3303 showed potent anabolic (levator ani muscle) agonist activity but only partial agonist activity on androgenic tissues (ventral prostate, preputial gland); tissue selectivity was maintained across both oral dosing and continuous infusion despite very different plasma exposure-time profiles (Vajda et al. 2009, PMID 19017848). In horses dosed orally at 0.05 mg/kg, eight metabolites (including hydroxylated and carboxylated forms with glucuronic acid conjugates) were tentatively identified in plasma and urine for doping-control purposes, with a monohydroxylated metabolite identified as the most sensitive analytical marker (Nilsson Broberg, Knych, Bondesson et al. 2023, PMID 37224728).
AC-262536 and LGD-3303 are both in the Performance category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs